Goldenwell Biotech Q2 FY26 net loss widens to $38,876; revenue remains no revenue

Reuters2026/08/14 18:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Goldenwell Biotech posted a net loss of USD 54,482 for the six months ended June 30, 2026, narrowing from USD 68,836.
Quarterly net loss widened to USD 38,876 for the three months ended June 30, 2026 from USD 30,300.
Revenue was unchanged at no revenue for the six months ended June 30, 2026.
General and administrative expense rose to USD 34,776 for the quarter from USD 28,200; six-month expense edged up to USD 66,111 from USD 64,636.
Cash totaled USD 11,143 at June 30, 2026; working capital was USD (398,195) with total liabilities of USD 427,173.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Goldenwell Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-005067), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldenwell Biotech Q2 FY26 net loss widens to $38,876; revenue remains no revenue

You may also like

Crypto prices